Loading
FRK is a SRC-related kinase that mostly acts as a brake on growth; it is a minor off-target of approved kinase inhibitors and is lost or mutated in some liver and brain cancers.
Fyn-related kinase (FRK) is a non-receptor tyrosine kinase of the SRC family that, unusually for the family, behaves as a tumour suppressor in several tissues: it stabilises PTEN, and its loss is reported in glioma, hepatocellular carcinoma and breast cancer. It is listed as a target of approved drugs because multi-kinase inhibitors such as dasatinib bind it, rather than because inhibiting it is the goal. Activating FRK fusions and mutations have been described in a minority of liver cancers, where kinase inhibition may be relevant.
In plain words · FRK is a SRC-related kinase that mostly acts as a brake on growth; it is a minor off-target of approved kinase inhibitors and is lost or mutated in some liver and brain cancers.
FRK is a SRC-related kinase that mostly acts as a brake on growth; it is a minor off-target of approved kinase inhibitors and is lost or mutated in some liver and brain cancers.
A nuclear and cytoplasmic SRC-family kinase expressed in epithelial tissues, brain and liver; it phosphorylates PTEN and retinoblastoma protein, slowing the cell cycle.
No product in this corpus aims at FRK kinase yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; the 1 medicine aimed at it (Dasatinib) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA FRK: RNA low tissue specificity; high antibody staining in 4 normal tissues; highest cancer staining liver cancer (2 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Brain and spinal cord tumours (all types), Hepatocellular carcinoma); Open Targets associates it with 3 specific cancer types at or above 0.5 (chronic myeloid leukemia, colorectal cancer, acute lymphoblastic leukemia). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas FRK tissue; Open Targets ENSG00000111816 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Cance W.G. et al, Int. J. Cancer, 1993, "Novel protein kinases expressed in human breast cancer". Source.
A nuclear and cytoplasmic SRC-family kinase expressed in epithelial tissues, brain and liver; it phosphorylates PTEN and retinoblastoma protein, slowing the cell cycle.
RNA: low tissue specificity, detected in many normal tissues.
Medium: Adrenal gland, Ovary, Parathyroid gland, Seminal vesicle, Smooth muscle, Stomach, Testis.
Medium only: lymphoma, pancreatic cancer, renal cancer, stomach cancer.
HPA FRK tissue · HPA FRK pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | all% | Signalling protein present in most cells (FRK kinase); drugs act on the pathway rather than on a mutation that selects patients, so no prevalence applies. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"FRK kinase" OR ABSTRACT:"FRK kinase" OR TITLE:"FRK" OR ABSTRACT:"FRK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FRK kinase, not a curated reading list.
Shares SRC family kinases, Dasatinib.
Shares Dasatinib, Glioma & glioblastoma.
Shares SRC family kinases, Dasatinib.
Shares SRC family kinases, Dasatinib.
Shares SRC family kinases, Dasatinib.